Prisinformation från TradingView

Bolagspresentation:

Nyhetsflöde Addvise Lab Solutions

Related articles:
8/10/2021 12:22:56 PM - Addvise Lab Solutions: Nya förvärv ger lyft - Mangold - Addvise har varit aktiva med förvärv under 2021 som väntas få stor påverkan på framtida resultatutveckling. Under juli slutfördes förvärvet av det amerikanska bolaget Medisuite som kommer att konsolideras från augusti. Detta väntas bidra till högre omsättning och förbättrad lönsamhet vilket Mangold behandlat i tidigare uppdatering.
8/2/2021 10:52:00 AM - Addvise Lab Solutions: Expanding in the US - Redeye - Redeye takes a positive stance to ADDvise’s acquisition of Medisuite. While it takes the net debt to EBITDA to a rather high level, we like ADDvise’s ambitious acquisition pace as adding size is important for smaller serial acquirers. We raise our Base case.
7/26/2021 7:57:15 AM - Addvise Lab Solutions: Q2’2021 Review: Improved Sales Mix Paying Off - Redeye - Redeye raises its forecast and Base case following a solid Q2 report beating our forecasts. While organic growth was negative, a stronger sales mix resulted in increased underlying EBITDA y/y. We expect the sales mix improvement to continue in H2 2021, resulting in rising EBITDA.
7/23/2021 10:38:56 AM - Addvise Lab Solutions: Q2’21, 9% EBIT Beat - Redeye - Redeye will likely increase its Base case and forecasts following a Q2 report, beating our EBIT forecasts by 9%. While losing the Covid-related government support present in Q2 2020, an improved sales mix with fewer consumables along with acquisitions led to unchanged reported EBIT. Considering ADDvise is trading at a significant discount to its larger peers, we believe building a track record of solid reports like this is vital.
5/19/2021 8:37:30 AM - Addvise Lab Solutions: Busy Last Week - Redeye - Redeye raises its Base case for ADDvise slightly following a busy week, including refinancing, a probable acquisition, and a large order.
4/26/2021 7:33:47 AM - Addvise Lab Solutions: Mot bättre tider - Mangold - Mangold uppdaterar Addvise
4/26/2021 5:20:20 AM - Addvise Q1 review: Another solid quarter - Redeye - Redeye remains positive to ADDvise following a stable quarter, where particularly Labs improved its EBITDA significantly YoY. Management seems optimistic regarding both demand and M&A activity, and the net debt is now at a healthy level. We leave our Base case and forecast unchanged while noting Q1 as another solid quarter.
4/23/2021 8:03:37 AM - Addvise Lab Solutions: Q1’21: Solid YoY improvement - Redeye - Redeye retains its positive view on ADDvise following a Q1 report showing a solid YoY improvement while being somewhat short of our expectations. While the Corona crisis had a negative impact during Q1, management saw an improvement by the end of the quarter. We will likely leave our forecasts largely unchanged.
3/26/2021 7:06:30 AM - Addvise: Revised forecasts and Base case - Redeye - Redeye revises its forecasts and Base case regarding ADDvise following a change of analyst. We expect increasing underlying margins in 2021 thanks to improved sales mix, and we raise our forecasts and Base case.
3/1/2021 2:46:01 PM - Addvise Lab Solutions: Laddar för nya förvärv - Mangold - Addvise, som förvärvar bolag inom medicinteknik, visade styrka under det utmanande pandemiåret 2020. Även om inga förvärv gjordes under året steg bolagets omsättning till 358,5 miljoner kronor, motsvarande en ökning om 2,5 procent. Det fjärde kvartalet visade något lägre omsättning än vad vi räknat med. Detta berodde på att marknaden går mot normalisering där utrustning för covid-19-patienter minskar och annan utrustning ökar.
1/18/2021 8:09:06 AM - Addvise Lab Solutions: Lovande serieförvärvare tar form - Mangold - Mangold tar upp bevakning av Addvise med rekommendationen köp och en riktkurs på 2,6 kronor på 12 månaders sikt.
8/3/2020 8:36:34 AM - Elva aktier har hittills i dag noterat nytt 52-veckorshögsta på Stockholmsbörsen - Hittills i dag har det bjudits på elva nya 52-veckorshögsta på Stockholmsbörsens listor.